Subcutaneous Amivantamab Noninferior to IV Administration in EGFR-Mutated NSCLC
Pelabresib Plus Ruxolitinib Significantly Reduces Splenomegaly in Myelofibrosis
Adjuvant Dabrafenib/Trametinib Maintains Long-Term Survival Benefit in Stage III Melanoma
Amivantamab Plus Lazertinib Improves PFS in High-Risk EGFR-Mutant NSCLC
2 Commerce Drive
Cranbury, NJ 08512